logo

For the Inventor, By the Inventor

Edison, NJ, United States of America

Rumin Zhang

This inventor holds 16 USPTO granted patents and 1 published patent application and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Schering Corporation, Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rumin Zhang. Retrieved from https://idiyas.com/inventor/rumin-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 50.0

 

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 141(Granted Patents)


Company Filing History:

goldMedal12 out of 1,829 
 
Schering Corporation
 patents
silverMedal3 out of 159 
 
Jiangsu Hengrui Medicine Company Ltd.
 patents
bronzeMedal3 out of 100 
 
Shanghai Hengrui Pharmaceutical Co., Ltd.
 patents
4. 1 out of 17 
 
Merck Gmbh
 patents
where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Benzimidazole Derivatives
CD73 Inhibitors
Polynucleotides
P53 Activity
HDM2 Polypeptides
Peptide Inhibitors
Kinase Ligands
HCV Protease
Azapeptides
Soluble Substrates
16 patents (USPTO):Explore Patents
1. 12187684 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof (2025-01-07),
2. 11512055 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof (2022-11-29),
3. 11332492 - CD73 inhibitors and therapeutic uses thereof (2022-05-17),
4. 8034907 - Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides (2011-10-11),
5. 7888474 - HDM2 polypeptides (2011-02-15),
6. 7884107 - Substituted piperidines that increase P53 activity and the uses thereof (2011-02-08),
7. 7705127 - HDM2 Polypeptides (2010-04-27),
8. 7632920 - Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof (2009-12-15),
9. 7592315 - Peptide viral entry inhibitors (2009-09-22),
10. 7511063 - High affinity quinoline-based kinase ligands (2009-03-31),
11. 7446195 - High affinity thiophene-based and furan-based kinase ligands (2008-11-04),
12. 7067273 - Peptide substrates of a proteolytic ADAM33 polypeptide and assays using the same (2006-06-27),
13. 6624290 - Azapeptides useful in the treatment of Hepatitis C (2003-09-23),
14. 6251583 - Peptide substrates for HCV NS3 protease assays (2001-06-26),
15. 5990276 - Synthetic inhibitors of hepatitis C virus NS3 protease (1999-11-23),

Title: Rumin Zhang: Innovator in Pharmaceutical Chemistry

Introduction

Rumin Zhang is a prominent inventor based in Edison, NJ, known for his significant contributions to pharmaceutical chemistry. With a total of 16 patents to his name, Zhang has made remarkable strides in the development of therapeutic agents.

Latest Patents

Among his latest patents are innovative benzimidazole derivatives that serve as modulators of the retinoid-related orphan receptor gamma (RORγ). These compounds are designed as inhibitors of the RORγ protein, and the inventions include pharmaceutical compositions containing these compounds, preparation methods, and their therapeutic applications for treating RORγ-mediated diseases or disorders.

Career Highlights

Zhang has had a distinguished career, working with notable companies such as Schering Corporation and Jiangsu Hengrui Medicine Company Ltd. His work has focused on advancing pharmaceutical solutions that address critical health issues.

Collaborations

Zhang has collaborated with esteemed colleagues, including William T. Windsor and Gerald Wayne Shipps, Jr. These partnerships have contributed to the success of his innovative projects.

Conclusion

Rumin Zhang's work in pharmaceutical chemistry exemplifies the impact of innovation in healthcare. His patents and collaborations highlight his commitment to developing effective therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…